Equities Analysts Issue Forecasts for Medpace Q3 Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP) – Stock analysts at William Blair decreased their Q3 2025 earnings estimates for shares of Medpace in a research report issued to clients and investors on Tuesday, February 11th. William Blair analyst M. Smock now forecasts that the company will post earnings of $2.99 per share for the quarter, down from their prior estimate of $3.18. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.93 per share. William Blair also issued estimates for Medpace’s Q4 2025 earnings at $2.93 EPS, FY2025 earnings at $12.12 EPS, Q1 2026 earnings at $3.38 EPS, Q2 2026 earnings at $3.44 EPS, Q3 2026 earnings at $3.50 EPS and Q4 2026 earnings at $3.57 EPS.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%.

A number of other equities analysts also recently issued reports on the stock. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Robert W. Baird increased their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Stock Up 2.6 %

Medpace stock opened at $336.47 on Thursday. Medpace has a 52-week low of $302.01 and a 52-week high of $459.77. The company has a market cap of $10.46 billion, a P/E ratio of 29.46, a P/E/G ratio of 1.85 and a beta of 1.36. The business has a 50-day simple moving average of $343.90 and a two-hundred day simple moving average of $348.96.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd purchased a new position in shares of Medpace during the 4th quarter valued at $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the fourth quarter valued at about $31,000. Stone House Investment Management LLC purchased a new position in shares of Medpace in the third quarter valued at about $33,000. Ashton Thomas Securities LLC purchased a new position in shares of Medpace in the third quarter valued at about $37,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after acquiring an additional 110 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.